More from Renaissance Capital
Referenced Stocks

Intercept Pharmaceuticals sets IPO terms

By Renaissance Capital,  September 27, 2012, 11:11:44 AM EDT

Intercept Pharmaceuticals, which is focused on the development and commercialization of therapeutics for chronic liver disease, announced terms for its IPO on Thursday. The New York, NY-based company plans to raise $60 million by offering 4.3 million shares at a price range of $13 to $15. At the midpoint of the proposed range, Intercept Pharmaceuticals would command a market value of $210 million. 

Intercept Pharmaceuticals, which was founded in 2002 and booked $3 million in revenue for the 12 months ended June 30, 2012, plans to list on the NASDAQ under the symbol ICPT. BofA Merrill Lynch is the lead bookrunner on the deal.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.


This article appears in: News Headlines, IPOs

Referenced Stocks: ICPT



Latest News Video



Sign-in
Existing NASDAQ.com member? Log in here.

By signing into to the site using any of the third-party services above, you agree to NASDAQ.com's Terms of Use.

From Our Trusted News Source





Most Active by Volume:

Company Last Sale Change Net / %
BAC $ 13.43 0.07  0.52%
CSCO $ 24.24 0.35  1.48%
MSFT $ 34.87 0.79  2.32%
F $ 15.08 0.44  3.01%
ARUN $ 13.10 4.51  25.61%
SIRI $ 3.50 0.05  1.45%
GE $ 23.46 0.19  0.82%
S $ 7.32 0.04  0.55%